{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:28Z","timestamp":1793316568751,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA150272P3"],"award-info":[{"award-number":["CA150272P3"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA196521"],"award-info":[{"award-number":["P30 CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish National Health Institute","award":["SAF 2016-76390"],"award-info":[{"award-number":["SAF 2016-76390"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tisch Cancer Institute"},{"name":"FSEOM"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jhep.2019.01.028","type":"journal-article","created":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T20:03:48Z","timestamp":1554062628000},"page":"1262-1277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0534-4246","authenticated-orcid":false,"given":"Josep M.","family":"Llovet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Montal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-3727","authenticated-orcid":false,"given":"Augusto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.01.028_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2019.01.028_b0010","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jhep.2019.01.028_b0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2019.01.028_b0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0045","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0050","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0065","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Randomised phase 3 trial of lenvatinib vs. sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.01.028_b0070","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0075","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0080","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2019.01.028_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.4_suppl.192","article-title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)","volume":"34","author":"Abou-Alfa","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0095","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2019.01.028_b0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.01.028_b0115","doi-asserted-by":"crossref","first-page":"15_supp","DOI":"10.1200\/JCO.2017.35.15_suppl.4000","article-title":"Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial","volume":"35","author":"Rimassa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0125","doi-asserted-by":"crossref","unstructured":"Zhu AX, Kang Y, Yen C, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;2045:1\u201315.","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"10.1016\/j.jhep.2019.01.028_b0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","article-title":"Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"29","author":"Abou-Alfa","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0135","article-title":"Safety and efficacy results from the phase 3 relive study of doxorubicin-loaded nanoparticles versus best standard of care in patients with advanced hepatocellular carcinoma after failure or intolerance to previous treatment including sorafenib","author":"Merle","year":"2017","journal-title":"Int Liver Cancer Assoc 11th Annu Conf"},{"key":"10.1016\/j.jhep.2019.01.028_b0140","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0150","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0155","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma","volume":"97","author":"Yeo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2019.01.028_b0160","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","article-title":"High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial","volume":"36","author":"Chow","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0165","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2019.01.028_b0170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase 3 studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes with sorafenib followed by regorafenib or placebo for HCC: additional analyses from the phase 3 RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0180","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0185","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0168-8278(18)30424-0","article-title":"The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort","volume":"68","author":"Ricke","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0190","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.01.028_b0195","unstructured":"FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib n.d. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm577166.htm."},{"key":"10.1016\/j.jhep.2019.01.028_b0200","unstructured":"Merck. Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma. February 19, 2019. Accessed at: https:\/\/investors.merck.com\/news\/press-release-details\/2019\/Merck-Provides-Update-on-KEYNOTE-240-a-Phase-3-Study-of-KEYTRUDA-pembrolizumab-in-Previously-Treated-Patients-with-Advanced-Hepatocellular-Carcinoma\/default.aspx."},{"key":"10.1016\/j.jhep.2019.01.028_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/jnci\/djs141","article-title":"Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer","volume":"104","author":"Gan","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2019.01.028_b0215","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"807\u2013823","key":"10.1016\/j.jhep.2019.01.028_b0220","article-title":"mTORC2 promotes tumorigenesis via lipid synthesis","volume":"32","author":"Guri","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2019.01.028_b0225","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.028_b0230","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70 S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0235","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2019.01.028_b0240","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2016.04.015","article-title":"Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma","volume":"65","author":"Zhu","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30025-1","article-title":"Negative phase 3 study of 90Y microspheres versus sorafenib in HCC","volume":"19","author":"Llovet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0255","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1158\/1078-0432.CCR-06-2844","article-title":"Sorafenib and sunitinib in renal cell carcinoma","volume":"13","author":"Stein","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0260","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1634\/theoncologist.2009-0316","article-title":"Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77\/06)","volume":"15","author":"Koeberle","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2019.01.028_b0270","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0275","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0280","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2019.01.028_b0285","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.028_b0290","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0295","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0300","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.05.035","article-title":"Genetic profiling of hepatocellular carcinoma using next-generation sequencing","volume":"65","author":"Schulze","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0305","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.028_b0310","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0315","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1158\/1078-0432.CCR-16-3118","article-title":"Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro","volume":"23","author":"Rebouissou","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0320","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0325","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2013.04.026","article-title":"KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development","volume":"12","author":"Goldman","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhep.2019.01.028_b0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.475","article-title":"Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040","volume":"36","author":"El-Khoueiry","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0335","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.01.028_b0340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0345","first-page":"27","article-title":"Studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma","author":"Lim","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0350","first-page":"1","article-title":"A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma","author":"Labgaa","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2019.01.028_b0355","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0360","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2019.01.028_b0365","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to Sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2019.01.028_b0370","article-title":"Activity of Blu-554, a Potent, Highly-Selective FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma (HCC) with FGFR4 Pathway Activation","author":"Kang","year":"2017","journal-title":"Int Liver Cancer Assoc 11th Annu Conf"},{"key":"10.1016\/j.jhep.2019.01.028_b0375","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0380","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.028_b0385","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2017.08.013","article-title":"Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma","volume":"67","author":"Torrecilla","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0390","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aat7171","article-title":"Minimal functional driver gene heterogeneity among untreated metastases","volume":"361","author":"Reiter","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jhep.2019.01.028_b0395","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2015.6645","article-title":"Noninferiority trials: is a new treatment almost as effective as another?","volume":"313","author":"Kaji","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2019.01.028_b0400","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0405","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2007.13.8156","article-title":"Reflections on medical oncology: 25 years of clinical trials\u2013where have we come and where are we going?","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0410","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0415","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0420","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0425","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the us food and drug administration\u2019s approval of oncology drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2019.01.028_b0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-018-0066-3","article-title":"Reinforcing the social compromise of accelerated approval","author":"Gyawali","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0435","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1107201","article-title":"Reputation and precedent in the bevacizumab decision","volume":"365","author":"Carpenter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0440","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1200\/JCO.2016.66.4581","article-title":"Surrogate end points and their validation in oncology clinical trials","volume":"34","author":"Zhao","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0445","unstructured":"Institute for Quality and Efficiency in Health Care [Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen] (IQWiG). Validity of surrogate endpoints in oncology: executive summary. n.d. http:\/\/www.iqwig.de\/download\/A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf."},{"key":"10.1016\/j.jhep.2019.01.028_b0450","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jclinepi.2015.02.016","article-title":"Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer","volume":"68","author":"Ciani","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jhep.2019.01.028_b0455","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.01.028_b0460","doi-asserted-by":"crossref","first-page":"052","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2019.01.028_b0465","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0470","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jhep.2019.01.028_b0475","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0480","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.27729","article-title":"Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib","volume":"62","author":"Iavarone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0485","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meanigful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0490","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.26255","article-title":"Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma","volume":"118","author":"Edeline","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2019.01.028_b0495","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2013-0114","article-title":"Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"19","author":"Ronot","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2019.01.028_b0500","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13104-015-1565-2","article-title":"Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma","volume":"8","author":"Takada","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jhep.2019.01.028_b0505","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0510","first-page":"1","article-title":"mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib","author":"Meyer","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.01.028_b0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070016","article-title":"Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response","volume":"8","author":"Cabibbo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.01.028_b0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis","volume":"10","author":"Vincenzi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.01.028_b0525","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/hep.20465","article-title":"Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma","volume":"40","author":"Sala","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0530","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization","volume":"55","author":"Gillmore","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0535","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejca.2012.08.022","article-title":"Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation","volume":"49","author":"Kim","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.01.028_b0540","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2013.01.039","article-title":"Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"58","author":"Jung","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.028_b0545","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mds605","article-title":"mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)","volume":"24","author":"Prajapati","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0550","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alpha or both for advanced renal cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0555","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0560","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.01.028_b0565","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0570","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0575","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0580","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Stephen Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0585","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1200\/JCO.2009.23.6018","article-title":"Ultimate fate of oncology drugs approved by the US food and drug administration without a randomized trial","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0590","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.2007.13.5913","article-title":"Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III","volume":"26","author":"El-Maraghi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0595","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4076","article-title":"A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)","volume":"36","author":"Ikeda","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0600","unstructured":"Hsu CH, Lee MS, Ryoo BY, Stein S, Lee KH, Verret W, et al. APASL: Safety and clinical activity results from atezolizumab (atezo) + bevacizumab (bev) in hepatocellular carcinoma (HCC): Updates from a Phase Ib study. Feb 22, 2019. Accessed at: https:\/\/medically.roche.com\/en\/search\/pdfviewer.cfd683a3-ef40-4777-99f5-402cdc61c904.html."},{"key":"10.1016\/j.jhep.2019.01.028_b0605","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4074","article-title":"Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)","volume":"36","author":"Stein","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0610","unstructured":"FDA Grants Breakthrough Therapy Designation for Genentech\u2019s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC) 2018. https:\/\/www.gene.com\/media\/press-releases\/14736\/2018-07-17\/fda-grants-breakthrough-therapy-designat?utm_source=F&utm_medium=P&utm_term=15538&utm_content=TecentriqHCCBTD&utm_campaign=TecentriqHCCBTD."},{"key":"10.1016\/j.jhep.2019.01.028_b0615","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamaoncol.2015.6315","article-title":"Response rate as a regulatory end point in single-arm studies of advanced solid tumors","volume":"2","author":"Oxnard","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0620","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1023\/A:1008996223999","article-title":"Recommendations on health-related quality of life research to support labeling and promotional claims in the United States","volume":"9","author":"Revicki","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2019.01.028_b0625","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: bridging the divide","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0630","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.24798","article-title":"International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques","volume":"55","author":"Chie","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0635","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","article-title":"Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of Cancer Therapy-Hepatobiliary Questionnaire","volume":"20","author":"Heffernan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0640","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0885-3924(02)00422-0","article-title":"Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: The FACT Hepatobiliary Symptom Index","volume":"24","author":"Yount","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jhep.2019.01.028_b0645","first-page":"e304","article-title":"Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma","author":"Chie","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.01.028_b0650","article-title":"Ramucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH)","volume":"68","author":"Llovet","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.028_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30222-8","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial","author":"Park","year":"2018","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819300753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819300753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T08:06:26Z","timestamp":1738483586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819300753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0168827819300753"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.01.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}